Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Bonella

Showing results (91-100 of 193) with videos related to

Pageof 20
Sort By:
ERJ Open Research|February 25, 2026
Circulating biomarkers in subjects with progressive pulmonary fibrosis: data from the INBUILD trialToby M Maher, R Gisli Jenkins, Francesco Bonella, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|August 30, 2011
Comparison of serum KL-6 versus bronchoalveolar lavage neutrophilia for the diagnosis of bronchiolitis obliterans in lung transplantationShinichiro Ohshimo, Francesco Bonella, Urte Sommerwerck, et al.
Respiration; International Review of Thoracic Diseases|October 12, 2018
Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Uncertainties and ControversiesZheng Wang, Francesco Bonella, Wenting Li, et al.
Nature Reviews. Disease Primers|August 9, 2020
Hypersensitivity pneumonitisUlrich Costabel, Yasunari Miyazaki, Annie Pardo, et al.
Respiration; International Review of Thoracic Diseases|August 22, 2016
Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary FibrosisFrancesco Bonella, Michael Kreuter, Lars Hagmeyer, et al.
Respiratory Medicine|May 20, 2014
Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosisShinichiro Ohshimo, Nobuhisa Ishikawa, Yasushi Horimasu, et al.
Journal of Clinical Medicine|November 14, 2023
Serum KL-6 as a Candidate Predictor of Outcome in Patients with SARS-CoV-2 PneumoniaSimone Kattner, Sivagurunathan Sutharsan, Marc Moritz Berger, et al.
Respiratory Research|September 25, 2015
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosisTamera Corte, Francesco Bonella, Bruno Crestani, et al.
Nature Reviews. Disease Primers|March 9, 2019
Pulmonary alveolar proteinosisBruce C Trapnell, Koh Nakata, Francesco Bonella, et al.
Journal of Clinical Medicine|June 26, 2026
KL-6 as a Biomarker for Adult Patients with Cystic Fibrosis and the Impact of <i>MUC1</i> GenotypeSarah Ricken, Sarah Dietz-Terjung, Gerhard Weinreich, et al.
Pageof 20

Showing results (91-100 of 193) with videos related to

Sort By:
Pageof 20
ERJ Open Research|February 25, 2026
Circulating biomarkers in subjects with progressive pulmonary fibrosis: data from the INBUILD trialToby M Maher, R Gisli Jenkins, Francesco Bonella, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|August 30, 2011
Comparison of serum KL-6 versus bronchoalveolar lavage neutrophilia for the diagnosis of bronchiolitis obliterans in lung transplantationShinichiro Ohshimo, Francesco Bonella, Urte Sommerwerck, et al.
Respiration; International Review of Thoracic Diseases|October 12, 2018
Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Uncertainties and ControversiesZheng Wang, Francesco Bonella, Wenting Li, et al.
Nature Reviews. Disease Primers|August 9, 2020
Hypersensitivity pneumonitisUlrich Costabel, Yasunari Miyazaki, Annie Pardo, et al.
Respiration; International Review of Thoracic Diseases|August 22, 2016
Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary FibrosisFrancesco Bonella, Michael Kreuter, Lars Hagmeyer, et al.
Respiratory Medicine|May 20, 2014
Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosisShinichiro Ohshimo, Nobuhisa Ishikawa, Yasushi Horimasu, et al.
Journal of Clinical Medicine|November 14, 2023
Serum KL-6 as a Candidate Predictor of Outcome in Patients with SARS-CoV-2 PneumoniaSimone Kattner, Sivagurunathan Sutharsan, Marc Moritz Berger, et al.
Respiratory Research|September 25, 2015
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosisTamera Corte, Francesco Bonella, Bruno Crestani, et al.
Nature Reviews. Disease Primers|March 9, 2019
Pulmonary alveolar proteinosisBruce C Trapnell, Koh Nakata, Francesco Bonella, et al.
Journal of Clinical Medicine|June 26, 2026
KL-6 as a Biomarker for Adult Patients with Cystic Fibrosis and the Impact of <i>MUC1</i> GenotypeSarah Ricken, Sarah Dietz-Terjung, Gerhard Weinreich, et al.
Pageof 20